First Trust Nasdaq Pharmaceuticals ETF
FTXH
18 hedge funds and large institutions have $6.18M invested in First Trust Nasdaq Pharmaceuticals ETF in 2025 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 3 closing their positions.
17% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 6
1.05% less ownership
Funds ownership: 44.89% → 43.84% (-1%)
9% less capital invested
Capital invested by funds: $6.79M → $6.18M (-$607K)
10% less funds holding
Funds holding: 20 → 18 (-2)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$322K |
| 2 |
LPL Financial
San Diego,
California
|
+$104K |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$84.4K |
| 4 |
Raymond James Financial
St Petersburg,
Florida
|
+$56.3K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$27.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OMC
Old Mission Capital
Chicago,
Illinois
|
-$433K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$219K |
| 3 |
WFA
WMG Financial Advisors
Knoxville,
Tennessee
|
-$52.5K |
| 4 |
VCM
Vivaldi Capital Management
Chicago,
Illinois
|
-$43.4K |
| 5 |
Envestnet Asset Management
Chicago,
Illinois
|
-$26.2K |
FTXH Hedge Fund Activity: Q2 2025 in Review
18 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in First Trust Nasdaq Pharmaceuticals ETF (FTXH) for Q2 2025, worth a combined $6.18M — down 8.9% from $6.79M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of FTXH and 1 opened new positions — a net loss of 2 holders — while 6 trimmed existing stakes and 7 added.
The largest buyer was Goldman Sachs, adding an estimated $322K. The largest seller was Old Mission Capital, exiting entirely with an estimated $433K sold.
- 18 institutional investors held First Trust Nasdaq Pharmaceuticals ETF (FTXH) as of Q2 2025, down from 20 in Q1 2025.
- Funds reported $6.18M of First Trust Nasdaq Pharmaceuticals ETF stock for Q2 2025, down 8.9% quarter-over-quarter.
- 1 fund opened new First Trust Nasdaq Pharmaceuticals ETF positions in Q2 2025 and 3 closed out, a net change of -2 holders.
- The largest First Trust Nasdaq Pharmaceuticals ETF buyer in Q2 2025 was Goldman Sachs, an estimated $322K added.
- The largest First Trust Nasdaq Pharmaceuticals ETF seller in Q2 2025 was Old Mission Capital, an estimated $433K sold.
Based on aggregated 13F filings for Q2 2025.